Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger

Cancer

Volumn 118, Issue 18, 2012, Pages 4619-4626

  Hoppe, Bradford S ^a   Nichols, Romaine C ^a   Henderson, Randal H ^a   Morris, Christopher G ^a   Williams, Christopher R ^a   Costa, Joseph ^a   Marcus Jr , Robert B ^a   Mendenhall, William M ^a   Li, Zuofeng ^a   Mendenhall, Nancy P ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

outcomes; prostate cancer; proton therapy; radiation therapy; toxicity

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; COBALT; PHOSPHODIESTERASE V INHIBITOR; PROTON; TESTOSTERONE;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; COHORT ANALYSIS; DIABETES MELLITUS; ERECTILE DYSFUNCTION; EXPANDED PROSTATE INDEX COMPOSITE QUESTIONNAIRE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION QUESTIONNAIRE; INTESTINE FUNCTION; MAJOR CLINICAL STUDY; MALE; PENIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTON THERAPY; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE; SCORING SYSTEM; SEXUAL INTERCOURSE; TREATMENT RESPONSE; URGE INCONTINENCE;

ADULT; COITUS; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PROTON THERAPY; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; URINARY INCONTINENCE;

EID: 84865989316     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27398     Document Type: Article

References (21)

1. Nelson CJ, Mulhall JP, Roth AJ,. The association between erectile dysfunction and depressive symptoms in men treated for prostate cancer. J Sex Med. 2011; 8: 560-566.
2. Helgason AR, Adolfsson J, Dickman P, Fredrikson M, Arver S, Steineck G,. Waning sexual function-the most important disease-specific distress for patients with prostate cancer. Br J Cancer. 1996; 73: 1417-1421.
3. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358: 1250-1261.
4. Ferrer M, Suárez JF, Guedea F, et al. Multicentric Spanish Group of Clinically Localized Prostate Cancer. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 72: 421-432.
5. Rice K, Hudak J, Peay K, et al. Comprehensive quality-of-life outcomes in the setting of a multidisciplinary, equal access prostate cancer clinic. Urology. 2010; 76: 1231-1238.
6. Pardo Y, Guedea F, Aguilõ F, et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol. 2010; 28: 4687-4696.
7. Vargas C, Fryer A, Mahajan C, et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70: 744-751.
8. Fontenot JD, Lee AK, Newhauser WD,. Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer. Int J Radiat Oncol Biol Phys. 2009; 74: 616-622.
9. Vargas C, Mahajan C, Fryer A, et al. Rectal dose-volume differences using proton radiotherapy and a rectal balloon or water alone for the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 2007; 69: 1110-1116.
10. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol. 2010; 28: 1106-1111.
11. Talcott JA, Rossi C, Shipley WU, et al. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA. 2010; 303: 1046-1053.
12. Coen JJ, Paly JJ, Niemierko A, et al. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011 May 26. [Epub ahead of print].
13. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG,. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000; 56: 899-905.
14. Schroeck FR, Donatucci CF, Smathers EC, et al. Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. Cancer. 2008; 113: 2687-2694.
15. Mendenhall NP, Li Z, Hoppe BS, et al. Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 82: 213-221.
16. Barry MJ,. Quality of life and prostate cancer treatment. J Urol. 1999; 162: 407.
17. Norman GR, Sloan JA, Wyrwich KW,. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003; 41: 582-592.
18. van der Wielen GJ, Hoogeman MS, Dohle GR, van Putten WL, Incrocci L,. Dose-volume parameters of the corpora cavernosa do not correlate with erectile dysfunction after external beam radiotherapy for prostate cancer: results from a dose-escalation trial. Int J Radiat Oncol Biol Phys. 2008; 71: 795-800.
19. Mangar SA, Sydes MR, Tucker HL, et al. MRC RT01 Trial Management Group. Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397). Radiother Oncol. 2006; 80: 355-362.
20. Wernicke AG, Valicenti R, Dieva K, Houser C, Pequignot E,. Radiation dose delivered to the proximal penis as a predictor of the risk of erectile dysfunction after three-dimensional conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 60: 1357-1363.
21. Roach M, Winter K, Michalski JM, et al. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys. 2004; 60: 1351-1356.